Antiviral therapy of chronic hepatitis B: Opportunities and challenges in Asia

Journal of Hepatology

Volumn 51, Issue 2, 2009, Pages 403-410

  Liaw, Yun Fan ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Chronic hepatitis B; Cost of drugs; Gross national income; Interferon ; Nucleos(t)ide analogs

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ENTECAVIR; LAMIVUDINE; PEGINTERFERON; PEGYLATED INTERFERON ALPHA 2A; PLACEBO; TELBIVUDINE; TENOFOVIR; UNCLASSIFIED DRUG;

ASIA; CHRONIC HEPATITIS; DISEASE COURSE; DRUG COST; HEALTH EDUCATION; HEALTH PROGRAM; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MEDICAL CARE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SCREENING;

ANTIVIRAL AGENTS; ASIA; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; FEMALE; HEPATITIS B, CHRONIC; HUMANS; MALE; MASS SCREENING; PREGNANCY;

EID: 67649224111     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.04.003     Document Type: Review

References (75)

1. Liaw Y.F., and Chu C.M. Hepatitis B virus infection. Lancet 373 (2009) 582-592
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11 (2004) 97-107
3. The World Bank. GNI 2007 Atlas Method. World development indicators database 2008 September. Available from: http://www.worldbank.org/.
4. Mohamed R., Desmond P., Suh D.J., Amarapurkar D., Gane E., Guangbi Y., et al. Practical difficulties in the management of hepatitis B in the Asia-Pacific region. J Gastroenterol Hepatol 19 (2004) 958-969
5. Lesmana L.A., Leung N.W.Y., Mahachai V., Phiet P.H., Suh D.J., Yao G.B., et al. Hepatitis B: overview of the burden of disease in the Asia-Pacific region. Liver Int 26 (2006) S3-S10
6. Weinbaum C.M., Williams I., Mast E.E., Wang S.A., Finelli L., Wasley A., et al. Centers for Disease Control and Prevention (CDC). Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 57 (2008) 1-20
7. Ryan J., and Tran T.T. Epidemiology and natural history of hepatitis B in Vietnam. Curr Hep B Rep 2 (2008) 133-136
8. Yurdaydin C., Bozdayi A.M., Idilman R., and Bozkaya H. HBV prevalence, natural history, and treatment in Eastern Europe, Turkey, and Turkish-Speaking Countries in Central Asia. Curr Hep B Rep 2 (2008) 137-142
9. Pan C., Jia J., Chu C.J., Hou J., and Hu K.Q. Epidemiology, presentation, and treatment of chronic HBV infection in Mainland China, in Taiwan, and in Chinese Americans in the United States. Curr Hep B Rep 2 (2008) 159-165
10. Han K.H., Park J.Y., and Min A.D. HBV prevalence, natural history, and treatment in Korea and the United States. Curr Hep B Rep 2 (2008) 166-172
11. Kao J.H. Role of viral factors in the natural course and therapy of chronic hepatitis B. Hepatol Int 1 (2007) 415-430
12. Chen D.S., Hsu N.H., Sung J.L., Hsu T.C., Hsu S.T., Kuo Y.T., et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 257 (1987) 2597-2603
13. Ni Y.H., Huang L.M., Chang M.H., Yen C.J., Lu C.Y., You S.L., et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 132 (2007) 1287-1293
14. Chen C.H., Yang P.M., Huang G.T., Lee H.S., Sung J.L., and Sheu J.C. Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc 106 (2007) 148-155
15. Chu C.M., and Liaw Y.F. Natural history differences in perinatally versus adult-acquired disease. Curr Hepatitis Rep 3 (2004) 123-131
16. Liaw Y.F. Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 18 (2003) 246-252
17. Hsu Y.S., Chien R.N., Yeh C.T., Sheen I.S., Chiou H.Y., Chu C.M., et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 35 (2002) 1522-1527
18. Chu C.M., Hung S.J., Lin J., Tai D.I., and Liaw Y.F. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 116 (2004) 829-834
19. Liaw Y.F., Sheen I.S., Chen T.J., Chu C.M., and Pao C.C. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 13 (1991) 627-631
20. Yuen M.F., Wong D.K., Sablon E., Tse E., Ng I.O., Yuan H.J., et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 39 (2004) 1694-1701
21. Chu C.M., and Liaw Y.F. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 45 (2007) 1187-1192
22. Chen Y.C., Chu C.M., Yeh C.T., and Liaw Y.F. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int 1 (2007) 267-273
23. Chen Y.C., Sheen I.S., Chu C.M., and Liaw Y.F. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 123 (2002) 1084-1089
24. Chu C.M., and Liaw Y.F. Spontaneous relapse of hepatitis in inactive HBsAg carrier. Hepatol Int 1 (2007) 311-315
25. Chu C.M., and Liaw Y.F. Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: a longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. J Hepatol 43 (2005) 411-417
26. Papatheodoridis G.V., Chrysanthos N., Hadziyannis E., Cholongitas E., and Manesis E.K. Longitudinal changes in serum HBV DNA levels and predictors of progression during the natural course of HBeAg-negative chronic hepatitis B virus infection. J Viral Hepat 15 (2008) 434-441
27. Hui C.K., Leung N., Yuen S.T., Zhang H.Y., Leung K.W., Lu L., et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 46 (2007) 395-401
28. Tai DI, Lin SM, Sheen IS, Chu CM, Lin DT, Liaw YF. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 2009. doi:10.1002/hep.22878.
29. Liaw Y.F., Tai D.I., Chu C.M., and Chen T.J. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 8 (1988) 493-496
30. Lin S.M., Yu M.L., Lee C.M., Chien R.N., Sheen I.S., Chu C.M., et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 46 (2007) 45-52
31. Chu C.M., and Liaw Y.F. Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis 26 (2006) 142-152
32. Fattovich G., Bortolotti F., and Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 48 (2008) 335-352
33. Yang H.I., Lu S.N., Liaw Y.F., You S.L., Sun C.A., Wang L.Y., et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 347 (2002) 168-174
34. Iloeje U.H., Yang H.I., Su J., Jen C.L., You S.L., and Chen C.J. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130 (2006) 678-686
35. Chen C.J., Yang H.I., Su J., Jen C.L., You S.L., Lu S.N., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295 (2006) 65-73
36. Liaw Y.F. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy. Antivir Ther 11 (2006) 669-679
37. IMS Health Taiwan. Taiwan hepatitis B disease awareness and attitude in general population 2005. [File of Bristol-Myers Squibb].
38. Lin S.Y., Chang E.T., and So S.K. Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatology 46 (2007) 1034-1040
39. Hann H.W., Hann R.S., and Maddrey W.C. Hepatitis B virus infection in 6,130 unvaccinated Korean-Americans surveyed between 1988 and 1990. Am J Gastroenterol 102 (2007) 767-772
40. Lai C.L., Chien R.N., Leung N.W., Chang T.T., Guan R., Tai D.I., et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339 (1998) 61-68
41. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348 (2003) 800-807
42. Marcellin P., Chang T.T., Lim S.G., Tong M.J., Sievert W., Shiffman M.L., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808-816
43. Marcellin P., Lau G.K.K., Bonino F., Farci P., Hadziyannis S., Jin R., et al. Peginterferon alfa-2a alone, lamivudine alone and the two in combination in patients with HBeAg negative chronic hepatitis B. N Engl J Med 351 (2004) 1206-1217
44. Lau G.K., Piratvisuth T., Luo K.X., Marcellin P., Thongsawat S., Cooksley G., et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352 (2005) 2682-2695
45. Chang T.T., Gish R.G., de Man R., Gadano A., Sollano J., Chao Y.C., et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 (2006) 1001-1010
46. Lai C.L., Shouval D., Lok A.S., Chang T.T., Cheinquer H., Goodman Z., et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354 (2006) 1011-1020
47. Sherman M., Yurdaydin C., Sollano J., Silva M., Liaw Y.F., Cianciara J., et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 130 (2006) 2039-2049
48. Lai C.L., Gane E., Liaw Y.F., Hsu C.W., Thongsawat S., Wang Y., et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357 (2007) 2576-2588
49. Marcellin P., Heathcote E.J., Buti M., Gane E., de Man R.A., Krastev Z., et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 359 (2008) 2442-2455
50. Chien R.N., Liaw Y.F., Atkins M., and for Asian Hepatitis Lamivudine Trial Group. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 30 (1999) 770-774
51. Liaw Y.F., Chien R.N., Yeh C.T., Tsai S.L., and Chu C.M. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30 (1999) 567-572
52. Song B.C., Suh D.J., Lee H.C., Chung Y.H., and Lee Y.S. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 32 (2000) 803-806
53. Chien R.N., Lin C.H., and Liaw Y.F. The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol 38 (2003) 322-327
54. Liaw Y.F., Sung J.J.Y., Chow W.C., Farrell G., Lee C.Z., Yuen H., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 (2004) 1521-1531
55. Leung N.W., Lai C.L., Chang T.T., Guan R., Lee C.M., Ng K.Y., et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33 (2001) 1527-1532
56. Liaw Y.F., Chang T.T., Wu S.S., Schiff E.R., Han K.H., Lai C.L., et al. Long-term entecavir therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in patients with HBeAg(+) and (-) chronic hepatitis B: results from studies ETV-022, -027 and -901. Hepatology 48 (2008) 706A abst 894
57. Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. Core Working Party for Asia-Pacific Consensus on Hepatitis B and C. J Gastroenterol Hepatol 2000;15:825-41.
58. Liaw Y.F., Leung N., Kao J.H., Piratvisuth T., Gane E., Han K.H., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2 (2008) 263-283
59. Li S.C., Ong S.C., Lim S.G., Yeoh K.G., Kwong K.S., Lee V., et al. A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore. J Clin Gastroenterol 38 (2004) S136-S143
60. Lee T.A., Veenstra D.L., Iloeje U.H., and Sullivan S.D. Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol 38 (2004) S144-S147
61. Hsieh C.R., and Kuo C.W. Cost of chronic hepatitis B virus infection in Taiwan. J Clin Gastroenterol 38 (2004) S148-S152
62. Yang B.M., Kim C.H., and Kim J.Y. Cost of chronic hepatitis B infection in South Korea. J Clin Gastroenterol 38 (2004) S153-S157
63. Brown R.E., De Cock E., Colin X., Antoñanzas F., and Iloeje U.H. Hepatitis B management costs in France, Italy, Spain, and the United Kingdom. J Clin Gastroenterol 38 (2004) S169-S174
64. Zhiqiang G., Zhaohui D., Qinhuan W., Dexian C., Yunyun F., Hingtao L., et al. Cost of chronic hepatitis B infection in China. J Clin Gastroenterol 38 (2004) S175-S178
65. Butler J.R.G., Pianko S., Korda R.J., Nguyen S., Gow P.J., Roverts S.K., et al. The direct cost of managing patients with chronic hepatitis B infection in Australia. J Clin Gastroenterol 38 (2004) S187-S192
66. Dan Y.Y., Aung M.O., and Lim S.G. The economics of treating chronic hepatitis B in Asia. Hepatol Int 2 (2008) 284-295
67. Hoofnagle J.H., Doo E., Liang T.J., Fleischer R., and Lok A.S. Management of hepatitis B: summary of a clinical research workshop. Hepatology 45 (2007) 1056-1075
68. Chien R.N., and Liaw Y.F. Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. Best Pract Res Clin Gastroenterol 22 (2008) 1081-1092
69. Tan N.C., and Cheah S.L. What barriers do primary care physicians face in the management of patients with chronic hepatitis B infection in primary care?. Singapore Med J 46 (2005) 333-339
70. In: Liaw Y.F. (Ed). Asia-Pacific pocket guide to hepatitis B (2006), University of Wisconsin Board of Regents and MDG Development Group, New Jersey
71. Liaw Y.F. Advancing the clinical treatment of hepatitis B virus in the Asian-Pacific region. Liver Int 26 (2006) 51-58
72. Namgyal P. Impact of hepatitis B immunization, Europe and worldwide. J Hepatol 39 (2003) S77-S82
73. Zanetti A.R., Van Damme P., and Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 26 (2008) 6266-6273
74. Keeffe E.B., Zeuzem S., Koff R.S., Dieterich D.T., Esteban-Mur R., Gane E.J., et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 5 (2007) 890-897
75. Liaw Y.F. On-treatment outcome prediction and adjustment during chronic hepatitis B therapy: now and future. Antivir Ther 14 (2009) 13-22